Literature DB >> 4868699

The plasma lecithins:cholesterol acyltransferase reaction.

J A Glomset.   

Abstract

Evidence for the existence of a plasma lecithin : cholesterol acyltransferase is reviewed with emphasis not only on the lipid reactants, but also on the lipoprotein "substrates" and "products." The cholesteryl esters of all major lipoprotein classes become labeled when plasma is incubated with cholesterol-(14)C. However, the smaller, lecithin-rich high density lipoproteins appear to be preferred substrates. Most studies of factors that influence the acyltransferase reaction have not adequately distinguished between effects on the enzyme and effects on the lipoprotein substrates. However, the fact that cholesterol esterification is diminished in plasma from eviscerated animals or from patients with reduced liver function suggests that the liver may regulate both the level of the enzyme and that of the substrates. Several indications exist that the acyltransferase reaction is the major source of plasma esterified cholesterol in man. Furthermore, the reaction may have a broader, extracellular function. One possibility is that it plays a role in the transport of cholesterol from peripheral tissues to the liver.

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 4868699

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  411 in total

1.  Amyloid fibrils derived from the apolipoprotein A1 Leu174Ser variant contain elements of ordered helical structure.

Authors:  P Mangione; M Sunde; S Giorgetti; M Stoppini; G Esposito; L Gianelli; L Obici; L Asti; A Andreola; P Viglino; G Merlini; V Bellotti
Journal:  Protein Sci       Date:  2001-01       Impact factor: 6.725

2.  Lecithin:cholesterol acyltransferase activity in hypercholesterolemic subjects and in hypercholesterolemic subjects treated with clofibrate.

Authors:  A D'Alessandro; A Zucconi; F Bellini; L Boncinelli; R Chiostri
Journal:  Lipids       Date:  1975-12       Impact factor: 1.880

Review 3.  New targets for medical treatment of lipid disorders.

Authors:  Margaret E Brousseau; Ernst J Schaefer
Journal:  Curr Atheroscler Rep       Date:  2002-09       Impact factor: 5.113

Review 4.  Model systems in cell culture for the study of atherogenesis Heinrich Wieland Award Lecture.

Authors:  Y Stein; O Stein
Journal:  Klin Wochenschr       Date:  1979-09-03

Review 5.  ATP binding cassette transporter A1--key roles in cellular lipid transport and atherosclerosis.

Authors:  Neelam Srivastava
Journal:  Mol Cell Biochem       Date:  2002-08       Impact factor: 3.396

6.  Phytosterol Esterification is Markedly Decreased in Preterm Infants Receiving Routine Parenteral Nutrition.

Authors:  Sara Savini; Alessio Correani; Daniele Pupillo; Rita D'Ascenzo; Chiara Biagetti; Adriana Pompilio; Manuela Simonato; Giovanna Verlato; Paola Cogo; Marina Taus; Albano Nicolai; Virgilio Paolo Carnielli
Journal:  Lipids       Date:  2016-09-24       Impact factor: 1.880

7.  Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice.

Authors:  Laurent Yvan-Charvet; Mollie Ranalletta; Nan Wang; Seongah Han; Naoki Terasaka; Rong Li; Carrie Welch; Alan R Tall
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

8.  Plasma lipoproteins in familial lecithin: cholesterol acyltransferase deficiency. Further studies of very low and low density lipoprotein abnormalities.

Authors:  J A Glomset; A V Nichols; K R Norum; W King; T Forte
Journal:  J Clin Invest       Date:  1973-05       Impact factor: 14.808

9.  A high cholesterol/cholate diet induced fatty liver in spontaneously hypertensive rats.

Authors:  K Ueno; H Okuyama
Journal:  Lipids       Date:  1986-08       Impact factor: 1.880

10.  Apolipoprotein A-I variants. Naturally occurring substitutions of proline residues affect plasma concentration of apolipoprotein A-I.

Authors:  A von Eckardstein; H Funke; A Henke; K Altland; A Benninghoven; G Assmann
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.